Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Innovent Biologics (IVBIY) collaborates with Roche (RHHBY) to develop the antibody-drug conjugate IBI3009 for small cell lung ...

Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.

Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with Roche (OTCQX:RHHBY) to develop its experimental lung cancer therapy ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate (ADC ...